Sort
40,608 grants matching “prostate cancer”
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2016 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2020 · CA
UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER SUPPORT GRANT
$629,550Kevin J Cullen · University Of Maryland Baltimore · P30 · FY2017 · CA
Proteolytic disregulation of the S326C mutant OGG1 DNA repair enzyme
$629,545Michele K Evans · National Institute On Aging · ZIA · FY2009 · AG
MRI Imaging and Biomarkers for Early Detection of Aggressive Prostate Cancer
$629,523Alan Pollack · University Of Miami School Of Medicine · U01 · FY2019 · CA
Men Moving Forward: A Lifestyle Intervention for African American Prostate Cancer Survivors
$629,520Melinda R Stolley · Medical College Of Wisconsin · R01 · FY2020 · CA
Phenotypic marker-guided development of selective antimetastasis therapeutic leads
$629,518Sui Huang · Northwestern University At Chicago · R01 · FY2023 · CA
A Targeted Nanomedicine Prototype Against Enzalutamide-resistant Prostate Cancer
$629,467Renata Pasqualini · Rbhs -Cancer Institute Of New Jersey · R01 · FY2022 · CA
Image-guided ultrasound ablation for precision targeting of prostate cancer
$629,446Everette C Burdette · Acoustic Medsystems, Inc. · R01 · FY2021 · CA
Advanced PET-CT Directed Post-Prostatectomy Radiotherapy to Enhance Prostate Cancer Outcomes
$629,419Ashesh Jani · Emory University · R01 · FY2019 · CA
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer
$629,362Iwao Ojima · State University New York Stony Brook · R01 · FY2024 · CA
Genetic profiling in PCPT: prostate cancer risk, PSA levels, and chemoprevention
$629,341Jianfeng Xu · Wake Forest University Health Sciences · R01 · FY2010 · CA
A Multiethnic Genome-Wide Scan of Prostate Cancer
$629,234Christopher Alan Haiman · University Of Southern California · U01 · FY2009 · HG
High throughput nanoplasmonic exosome testing (NEXT) of immunotherapies in bladder cancer
$629,224Cesar M Castro · Massachusetts General Hospital · R01 · FY2024 · CA
NOTCH signaling controls transformation to androgen independent neuroendocrine prostate cancer
$629,075David W Goodrich · Roswell Park Cancer Institute Corp · R01 · FY2023 · CA
NCI NCTN- Network Lead Academic Participating Site: USC
$629,001Heinz Josef Lenz · University Of Southern California · U10 · FY2014 · CA
Targeting the PI3K Signaling Axis
$628,967Thomas M Roberts · Massachusetts General Hospital · P50 · FY2015 · CA
DEALING WITH A PRICKLY SITUATION: HOW STATINS AND SELECTIVE ESTROGEN RECEPTOR MODULATORS INHIBIT HEDGEHOG SIGNALING AND STOP PROSTATE CANCER
$628,946University Of Missouri System · · FY2011 · Department of the Army
Germline Determinants of Prostate Cancer Evolution
$628,946Paul Christopher Boutros · University Of California Los Angeles · R01 · FY2023 · CA
Project 3: Spherical Nucleic Acids as Immunotherapeutic Agents for Prostate Cancer
$628,901Chad A. Mirkin · Northwestern University At Chicago · U54 · FY2017 · CA
Risk-stratification of Prostate Cancers via Field Carcinogenesis Nanocytology
$628,861Vadim Backman · Northwestern University · R01 · FY2018 · CA
Thermoregulatory Physiology of Menopausal Hot Flashes
$628,753Fiona C Baker · Sri International · R21 · FY2025 · AG
Genetic & epigenetic analysis of angiogenesis genes in recurrent prostate cancer
$628,729Jong Y Park · H. Lee Moffitt Cancer Ctr & Res Inst · R01 · FY2009 · CA
Commercial development of Src kinase inhibitors for oncology
$628,719Allen Barnett · Kinex Pharmaceuticals, Llc · R44 · FY2009 · CA
Optimizing prostate cancer care: integrating risks, benefits, and patient experiences in the new era of molecular imaging
$628,694Michael Stuart Leapman · Yale University · R01 · FY2024 · CA